Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Facebook
  • Twitter
  • Google+
  • Pinterest

NCI Drug Dictionary

  

pegylated recombinant L-asparaginase Erwinia chrysanthemi 
A pegylated, recombinant form of L-asparaginase derived from the bacterium Erwinia chrysanthemi (mPEG-R-crisantaspase), with potential antineoplastic activity. Upon intravenous administration of pegylated recombinant L-asparaginase Erwinia chrysanthemi, asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cancer cells of asparagine thus blocking protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Compared to other available Erwinia chrysanthemi derived L-asparaginase agents, the pegylated form is longer acting and less immunogenic. Check for active clinical trials or closed clinical trials using this agent.
Synonym:mPEG-R-crisantaspase
Foreign brand name:Asparec